ZYDUS LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,104 INR | +5.00% |
|
+12.40% | +60.18% |
| 10:48am | Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold | MT |
| 17/05 | Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 195B 2.35B | Sales 2025 * | 214B 2.57B | Capitalization | 1,111B 13.35B |
|---|---|---|---|---|---|
| Net income 2024 | 38.6B 464M | Net income 2025 * | 43.37B 521M | EV / Sales 2024 | 5.19 x |
| Net cash position 2024 * | 13.47B 162M | Net cash position 2025 * | 33.33B 400M | EV / Sales 2025 * | 5.02 x |
| P/E ratio 2024 |
26.4
x | P/E ratio 2025 * |
26.1
x | Employees | 23,026 |
| Yield 2024 * |
0.52% | Yield 2025 * |
0.5% | Free-Float | 24.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zydus Lifesciences Limited
More recommendations
More press releases
| 1 day | +5.00% | ||
| 1 week | +12.40% | ||
| Current month | +15.77% | ||
| 1 month | +19.71% | ||
| 3 months | +21.64% | ||
| 6 months | +73.43% | ||
| Current year | +60.18% |
1 week
978.50
1 103.95
1 month
914.501 103.95
Current year
686.001 103.95
1 year
484.951 103.95
3 years
319.001 103.95
5 years
202.001 103.95
10 years
178.451 103.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 44 | 01/97/01 | |
| Director of Finance/CFO | - | - | |
| Chairman | 71 | 15/95/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 06/18/06 | |
| Chairman | 71 | 15/95/15 | |
| Director/Board Member | 69 | 01/97/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 6 M€ | +6.07% | - | |
| 0.01% | 112 M€ | +5.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 1,104 | +5.00% | 71,808 |
| 17/24/17 | 1,051 | +4.20% | 3,018,435 |
| 16/24/16 | 1,009 | +1.20% | 1,608,100 |
| 15/24/15 | 997 | +1.36% | 1,174,315 |
| 14/24/14 | 983.6 | -0.89% | 799,850 |
Delayed Quote NSE India S.E., May 18, 2024 at 12:47 pm IST
More quotes
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
1,104
INR
Average target price
890.1
INR
Spread / Average Target
-19.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.18% | 13.34B | |
| +21.63% | 44.12B | |
| +22.99% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.61B | |
| -8.35% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B | |
| +6.11% | 4.77B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
